CytomX Therapeutics provided an update on its CX-2051 Phase 1 study, stating that the CTMX-2051-101 study has enrolled 73 colorectal cancer patients to date. This update was issued to address recent social media posts regarding the program.
The company confirmed that Phase 1 enrollment for CX-2051 is substantially complete. CytomX remains on track to provide a data update for the CX-2051 program in the first quarter of 2026.
Patients continue to be dosed with CX-2051 across all expansion doses, underscoring the ongoing progress and commitment to advancing this lead program for the treatment of colorectal cancer. Patient safety remains a top priority for the company.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.